IRLAB Therapeutics AB announced that the company’s drug candidate IRL757 has completed all preclinical studies and development work necessary to start Phase I.
IRLAB Therapeutics AB announced that the company’s drug candidate IRL757 has completed all preclinical studies and development work necessary to start Phase I.